ALNY

#289
Alnylam Pharmaceuticals, Inc.
332.92
+0.42%
Setor:
Base:
Moeda do lucro:
Faixa diária
332.77
332.92
Faixa anual
205.87
495.55
Mudança diária
+0.42%
Mudança mensal
-5.86%
Mudança em 6 meses
-26.35%
Mudança anual
+40.72%
Fechamento anterior
331.54
Open
332.77
Bid
Ask
Low
332.77
High
332.92
Volume
379
Open full chart

Financials

Overview Relatórios Statistics Dividends
Quarterly Annual
  • Market Capitalization 43.61 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
170.67
Price to sales ratio
14.42
Dividends per share
—
Dividend yield %
—

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Notícias